A new analysis found that eating both oily fish and wholemeal/wholegrain bread may help lower one's risk of developing ...

Sanofi will not be pursuing approval of tolebrutinib for PPMS, and an FDA decision on the therapy in nonrelapsing SPMS will ...

Tolebrutinib failed to meet the primary endpoint in the phase 3 PERSEUS study involving patients with primary progressive multiple sclerosis.

In pediatric-onset multiple sclerosis, switching to oral or infusion therapies was linked to fewer relapses than switching between injectable treatments.

The over‐the‐counter supplement lipoic acid may have a small beneficial effect in slowing the loss of gray matter in the ...

New research reveals that when gut bacteria closely resemble the myelin sheath that protects nerve fibers, the immune system can become confused and attack both — accelerating multiple sclerosis.

Sanofi drug faces FDA delay following a failed late-stage trial for multiple sclerosis, with regulatory guidance expected by Q1 2024.

Sanofi’s multiple sclerosis hopeful tolebrutinib faced dual setbacks on Monday, with a late-stage failure in one form of the ...

So continues the rocky path for the drug, which Sanofi picked up in its $3.7 billion buyout of Principia Biopharma back in ...

If gut bacteria are too similar to the protective layer of nerves, they can misdirect the immune system and cause it to ...

Dec 15 () - Shares of French pharmaceutical group Sanofi fell 4% on Monday after it flagged another delay to ​a U. regulatory ...

Sanofi shares slide after FDA delays review of its MS drug tolebrutinib and a late-stage trial fails to meet its main goal.